Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
1 clinical trials · Condition
◉ Watch Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (NCT05256225) | National Cancer Institute (NCI) | 2022-11-16 |
Track Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor automatically
Every clearance here is in the API, with alerts when new ones post.